10 Pro-Life Companies to Invest In Now

8. Haemonetics Corp (NYSE:HAE)

Number of Hedge Funds: 28

​Haemonetics Corp (NYSE:HAE) is a global healthcare company specializing in blood management solutions. Its portfolio includes devices, information management systems, and consulting services aimed at optimizing blood and plasma collection, surgical blood salvage, and hospital transfusion services. Haemonetics Corp (NYSE:HAE) operates across various medical markets, providing products for surgical blood salvage, blood component collections, and plasma collections worldwide.

Haemonetics Corp (NYSE:HAE) recently completed the sale of its whole blood assets to GVS S.p.A. in January 2025, enabling the company to focus on high-growth areas within blood management. In March 2025, Haemonetics appointed Frank W. Chan, Ph.D., as Executive Vice President, leveraging his 25+ years of leadership experience in medical devices and healthcare technology to strengthen strategic initiatives. Frank has previously held a key leadership position as President of the Medtronic Acute Care & Monitoring (ACM) business.

Haemonetics Corp (NYSE:HAE) reported a total revenue of $1.31 billion over the past year, reflecting a 12.01% increase, driven by strong sales growth and operational efficiencies. As of March 25, 2025, Haemonetics’ stock trades at $64.45, with a market cap of $3.23 billion. Analysts remain bullish, with 82% of 11 analysts rating it a “Buy” and a median price target of $97.50, suggesting a 51.28% upside potential, as of March 25th.